Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor. England, K., S., Tumber, A., Krojer, T., Scozzafava, G., Ng, S., S., Daniel, M., Szykowska, A., Che, K., Von Delft, F., Burgess-Brown, N., A., Kawamura, A., Schofield, C., J., & Brennan, P., E. MedChemComm, 5(12):1879-1886, The Royal Society of Chemistry, 2014.
Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor [pdf]Paper  Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor [link]Website  doi  abstract   bibtex   

Compound 35 is a potent and selective triazolopyridine inhibitor of the lysine demethylase KDM2A (pIC 50 7.2).


Downloads: 0